Novo Nordisk A/S
XMUN:NOVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
SE |
|
U
|
Urban Lithium Inc
KOSDAQ:073570
|
KR |
Economic Moat
Novo Nordisk A/S has a wide economic moat
Legal protection for key medicines prevents rivals from selling direct copies in major markets, helping Novo Nordisk keep profits from its diabetes and obesity treatments. Competitors must develop different medicines and prove they work rather than simply copy its protected products.
What protects Novo Nordisk A/S from competitors
Intangible Assets
Patents protecting semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus, block direct copies in major markets where protection remains in force. Rivals such as Eli Lilly compete with different approved medicines, but cannot freely copy Novo Nordisk’s protected treatments and undercut their prices.
What could weaken Novo Nordisk A/S's moat
Patent protection ends
Patent expiry or successful legal challenges would allow approved lower-priced copies to compete directly with Novo Nordisk’s protected medicines.
